We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




FDA Proposes New Draft Guidance for Diagnostic, Radiology Devices

By LabMedica International staff writers
Posted on 21 Jul 2011
Print article
The US Food and Drug Administration (Silver Spring, MD, USA) has eased premarket notification requirements for certain in vitro diagnostic and radiology devices with well-established safety and effectiveness profiles.

The draft guidance lists 30 different device types, including common urine and blood tests, alcohol breath tests, blood clotting protein tests, and radiology device accessories, such as film cassettes, film processors, and digitizers. FDA intends to exempt these devices from premarket notification requirements through the appropriate regulatory processes. In the meantime, however, FDA does not intend to enforce the premarket notification requirements with respect to these devices provided that they do not exceed the limitations on exemption specified in the device classification regulations.

In the future, the FDA also intends to reduce the premarket regulatory burden on additional in vitro diagnostic and radiology device types.

"The safety and effectiveness of these devices have been well demonstrated over the years," said Jeffrey Shuren, MD, director of FDA's Center for Devices and Radiological Health. "By addressing the risk level of these devices, the agency is taking a smart regulatory approach that eases unnecessary requirements for manufacturers, while making sure the public has safe and effective devices."

The device types listed in the draft guidance include devices identified by the FDA as those for which less stringent oversight would not compromise public health.

The FDA is seeking further comment on the draft guidance from manufacturing, clinical, and patient communities. The draft guidance is open for comment for 90 days.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.

For more information regarding the enforcement policy for premarket notification requirements for certain in vitro diagnostic and radiology devices please see Related Links below.

Related Links:
US Food and Drug Administration
US FDA Medical Device Regulation and Guidance Document

New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Testosterone Assay
Testosterone ELISA (REF 21-02)
New
Hematology Analyzer
XS-500i

Print article

Channels

Microbiology

view channel
Image: Genetic testing can determine which drugs will work for patients with C. auris (Photo courtesy of Shutterstock)

Genetic Testing Could Improve Treatment for Virulent Multidrug-Resistant Fungus Candida Auris

Candida auris (C. auris), a multidrug-resistant yeast responsible for severe, life-threatening infections, was first identified in 2009. Since its discovery, it has spread globally, causing significant... Read more

Pathology

view channel
Image: The unique AI tool predicts cancer prognoses and responses to treatment (Photo courtesy of Shutterstock)

AI Tool Combines Data from Medical Images with Text to Predict Cancer Prognoses

The integration of visual data (such as microscopic and X-ray images, CT and MRI scans) with textual information (like exam notes and communications between doctors of different specialties) is a crucial... Read more

Industry

view channel
Image: The investment is in line with Danaher’s aim to accelerate the transition to precision medicine with AI-enabled diagnostics

Danaher Partners with Healthcare AI Company Innovaccer on Novel Digital and Diagnostic Solutions

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (Washington, DC, USA), has formed an investment partnership with healthcare artificial intelligence (AI) company... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.